Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25532196 | 1.00 | ROCK2 (0.51) | ROCK2CYP19A1MCHR1SLC18A3HTR1A | |
| SCHEMBL22254159 | 1.00 | ROCK2 (0.51) | ROCK2CYP19A1MCHR1SLC18A3HTR1A | |
| SCHEMBL22254489 | 0.88 | ROCK2 (0.49) | ROCK2MCHR1GBA1S1PR5DPP4 | |
| SCHEMBL25532118 | 0.88 | ROCK2 (0.49) | ROCK2MCHR1GBA1S1PR5DPP4 | |
| SCHEMBL25553818 | 0.88 | ROCK2 (0.49) | ROCK2MCHR1GBA1S1PR5DPP4 | |
| SCHEMBL22254188 | 0.88 | ROCK2 (0.50) | ROCK2MCHR1S1PR5S1PR4S1PR1 | |
| SCHEMBL22254828 | 0.88 | ROCK2 (0.50) | ROCK2CYP19A1MCHR1DPP4DPP8 | |
| SCHEMBL22254182 | 0.88 | ROCK2 (0.50) | ROCK2CYP19A1MCHR1DPP4DPP8 | |
| SCHEMBL22254165 | 0.88 | ROCK2 (0.50) | ROCK2MCHR1S1PR5S1PR4S1PR1 | |
| SCHEMBL22254158 | 0.88 | ROCK2 (0.50) | ROCK2CYP19A1MCHR1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| WO-2020150385-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | ROCK2 2850/4885CYP19A1 4397/4885MCHR1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.